Azoulay Salomon sold 373 shares of MBX Biosciences, Inc. at $53.96 for −$20.1k on Nov 4, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed Nov 5, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$20,127.08Shares × reported price
Shares traded
373Common Stock
Price per share
$53.96Reported price. Read footnotes for ranges.
% of reported position traded
2.59%This security and ownership context
Holdings after
14,026Direct
Trade date
Nov 4, 2026Sell
Filed
Nov 5, 2026, 4:10 PM ET1-day reporting delay
Accession
0001193125-26-449832Code S · Transaction 393462
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 14,399 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

MBX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MBX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +21%1w ago +12%1d ago +13%
Returns since7d +12%30d90d180d1y

Footnotes in full

F1: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $51.78 to $56.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.